Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan

 Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan

Mundipharma Collaborates with Samsung Bioepis to Commercialize Multiple Biosimilar Candidates in Hong Kong and Taiwan

Shots:

  • Mundipharma to get exclusive commercialization rights for Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong while Samsung Bioepis will remain MAH, responsible for the development, regulatory and manufacturing activities of therapies
  • The biosimilar candidates include SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab) targeting immunology & oncology
  • The collaboration combines Samsung Bioepis’ biosimilar development platform with Mundipharma’s commercial acumen and market insight to address the medical needs of patients in the licensed territories

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post